13196-10-6Relevant academic research and scientific papers
Synthetic models related to methoxalen and menthofuran-cytochrome P450 (CYP) 2A6 interactions. Benzofuran and coumarin derivatives as potent and selective inhibitors of CYP2A6
Yamaguchi, Yuki,Akimoto, Ichie,Motegi, Kyoko,Yoshimura, Teruki,Wada, Keiji,Nishizono, Naozumi,Oda, Kazuaki
, p. 997 - 1001 (2013)
Human microsomal cytochrome P450 (CYP) 2A6 contributes extensively to nicotine detoxication but also activates tobacco-specific procarcinogens to mutagenic products. We prepared a series of benzofuran and coumarin derivatives that have inhibitory effects on the activity of human CYP2A6. The reported compounds methoxalen and menthofuran had potent inhibitory effects on the activity of CYP2A6 with IC50 values of 0.47 μM and 1.27 μM, respectively. Synthetic benzofuran (4-methoxybenzofuran: IC50=2.20 μM) and coumarin (5-methoxycoumarin: IC50=0.13 μM and 6-methoxycoumarin: IC50=0.64 μM) derivatives, which have more selective effects than those of methoxalen and menthofuran, exhibited comparable activities against CYP2A6. These compounds can be used as a lead compounds in the design of CYP2A6 inhibitor drugs to reduce smoking and tobacco-related cancers.
New heteroaryl carbamates: Synthesis and biological screening in vitro and in mammalian cells of wild-type and mutant HIV-protease inhibitors
Tramutola, Francesco,Armentano, Maria Francesca,Berti, Federico,Chiummiento, Lucia,Lupattelli, Paolo,D'Orsi, Rosarita,Miglionico, Rocchina,Milella, Luigi,Bisaccia, Faustino,Funicello, Maria
, p. 1863 - 1870 (2019)
New heteroaryl HIV-protease inhibitors bearing a carbamoyl spacer were synthesized in few steps and high yield, from commercially available homochiral epoxides. Different substitution patterns were introduced onto a given isopropanoyl-sulfonamide core that can have either H or benzyl group. The in vitro inhibition activity against recombinant protease showed a general beneficial effect of both carbamoyl moiety and the benzyl group, ranging the IC50 values between 11 and 0.6 nM. In particular, benzofuryl and indolyl derivatives showed IC50 values among the best for such structurally simple inhibitors. Docking analysis allowed to identify the favorable situation of such derivatives in terms of number of interactions in the active site, supporting the experimental results. The inhibition activity was also confirmed in HEK293 mammalian cells and was maintained against protease mutants. Furthermore, the metabolic stability was comparable with that of the commercially available inhibitors.
Facile entry to 4- and 5-hydroxybenzofuran and to their amino derivatives
Bonini, Carlo,Cristiani, Graziella,Funicello, Maria,Viggiani, Licia
, p. 1983 - 1990 (2006)
An innovative one-step procedure for the synthesis of 4-hydroxybenzofuran and an improved synthesis of 5-hydroxybenzofuran is reported. Such compounds were also transformed into their amino derivatives via Smiles rearrangement with good to high overall yields. Copyright Taylor & Francis Group, LLC.
Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand
Prime, Michael E.,Liu, Longbin,Lee, Matt R.,Khetarpal, Vinod,Brown, Christopher J.,Johnson, Peter D.,Miranda-Azpiazu, Patricia,Chen, Xuemei,Clark-Frew, Daniel,Coe, Samuel,Davis, Randall,Dickie, Anthony,Ebneth, Andreas,Esposito, Simone,Gadouleau, Elise,Gai, Xinjie,Galan, Sebastien,Green, Samantha,Greenaway, Catherine,Giles, Paul,Halldin, Christer,Hayes, Sarah,Herbst, Todd,Herrmann, Frank,He?mann, Manuela,Jia, Zhisheng,Kiselyov, Alexander,Kotey, Adrian,Krulle, Thomas,Mangette, John E.,Marston, Richard W.,Menta, Sergio,Mills, Matthew R.,Monteagudo, Edith,Nag, Sangram,Nibbio, Martina,Orsatti, Laura,Schaertl, Sabine,Scheich, Christoph,Sproston, Joanne,Stepanov, Vladimir,Svedberg, Marie,Takano, Akihiro,Taylor, Malcolm,Thomas, Wayne,Toth, Miklós,Vaidya, Darshan,Vanr?s, Katarina,Weddell, Derek,Wigginton, Ian,Wityak, John,Mrzljak, Ladislav,Munoz-Sanjuan, Ignacio,Bard, Jonathan A.,Dominguez, Celia
, p. 8608 - 8633 (2020)
Mutant huntingtin (mHTT) protein carrying the elongated N-Terminal polyglutamine (polyQ) tract misfolds and forms protein aggregates characteristic of Huntington's disease (HD) pathology. A high-Affinity ligand specific for mHTT aggregates could serve as a positron emission tomography (PET) imaging biomarker for HD therapeutic development and disease progression. To identify such compounds with binding affinity for polyQ aggregates, we embarked on systematic structural activity studies; lead optimization of aggregate-binding affinity, unbound fractions in brain, permeability, and low efflux culminated in the discovery of compound 1, which exhibited target engagement in autoradiography (ARG) studies in brain slices from HD mouse models and postmortem human HD samples. PET imaging studies with 11C-labeled 1 in both HD mice and WT nonhuman primates (NHPs) demonstrated that the right-hand-side labeled ligand [11C]-1R (CHDI-180R) is a suitable PET tracer for imaging of mHTT aggregates. [11C]-1R is now being advanced to human trials as a first-in-class HD PET radiotracer.
2-Nitrofurans as dienophiles in Diels-Alder reactions
Rosa, Claudia Della,Kneeteman, María N.,Mancini, Pedro M.E.
, p. 8711 - 8714 (2005)
α-Nitrofuran derivatives are studied in Diels-Alder reactions under thermal conditions. In contrast to α-acylfurans, they proved to be efficient dienophiles.
Synthesis, characterization, and properties of a benzofuran-based cage-shaped borate: Photo activation of Lewis acid catalysts
Konishi, Akihito,Yasunaga, Ryosuke,Chiba, Kouji,Yasuda, Makoto
, p. 3348 - 3351 (2016)
A cage-shaped borate with benzofuran moieties was synthesized. This borate showed a higher degree of catalytic activity for Mukaiyama-aldol type reactions than a simple benzene-based cage-shaped borate induced by self-aggregation. Moreover, the exposure of the complex to black-light irradiation enhanced the catalytic activity.
TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND
-
Paragraph 0101-0102, (2021/07/17)
Disclosed is a series of tricyclic substituted piperidine dione compounds, and applications thereof in the preparation of medicines for treating diseases related to CRBN protein; specifically disclosed are the derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
Immunoproteasome Inhibitor-Doxorubicin Conjugates Target Multiple Myeloma Cells and Release Doxorubicin upon Low-Dose Photon Irradiation
Dekker, Patrick M.,Florea, Bogdan I.,Maiorana, Santina,Maurits, Elmer,Neefjes, Jacques J. C.,Overkleeft, Herman S.,Van De Graaff, Michel J.,Van Der Zanden, Sabina Y.,Van Kasteren, Sander I.,Wander, Dennis P. A.
, p. 7250 - 7253 (2020/08/06)
Proteasome inhibitors are established therapeutic agents for the treatment of hematological cancers, as are anthracyclines such as doxorubicin. We here present a new drug targeting approach that combines both drug classes into a single molecule. Doxorubicin was conjugated to an immunoproteasome-selective inhibitor via light-cleavable linkers, yielding peptide epoxyketone-doxorubicin prodrugs that remained selective and active toward immunoproteasomes. Upon cellular uptake and immunoproteasome inhibition, doxorubicin is released from the immunoproteasome inhibitor through photoirradiation. Multiple myeloma cells in this way take a double hit: immunoproteasome inhibition and doxorubicin-induced toxicity. Our strategy, which entails targeting of a cytotoxic agent, through a covalent enzyme inhibitor that is detrimental to tumor tissue in its own right, may find use in the search for improved anticancer drugs.
Method suitable for large-scale production of B-RAF kinase dimer inhibitor
-
, (2020/08/18)
The invention relates to a method for large-scale production of a B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-diazanaphthalene-4-yl) oxy)-1a, 6b-dihydro-1H-cyclopropyl [b] benzofuran-1-yl)-3-(2, 4, 5- trifluorophenyl) urea (hereinafter sometimes referred to as a compound 1). The method enables impurities or by-products to be controlled to 0.05% or less without the use of expensive column chromatography operations. Thus, the method greatly reduces cost and is suitable for large-scale production.
Stable crystalline form A of B-RAF kinase dimer inhibitor
-
, (2020/08/18)
The invention relates to a stable crystalline form A of a B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-diazanaphthalene-4-yl) oxy)-1a, 6b-dihydro-1H-cyclopropyl[b] benzofuran-1-yl)-3-(2, 4, 5- trifluorophenyl) urea (hereinafter sometimes referred to as a compound 1), a preparation method of the crystalline Form A and therapeutic use of the crystalline Form A.
